The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
A novel, potent, orally bioavailable antagonist of P2X3/P2X2/3 receptors (pIC50 = 8 in human and rat; pIC50 = 7.3 for human P2X2/3 receptor). Shown to be highly brain penetrant with a brain to plasma ratio of 6. Blocks agonist-evoked intracellular Ca2+ flux and inward currents in nanomolar range (10 nM to 1 µM) in cell lines recombinantly expressing human P2X3 and P2X2/3 receptors. Exhibits desirable pharmacokinetic properties (t1/2 = 1.63 h and Tmax = 30 min).
Gever, J. R., et al. 2010. Br. J. Pharmacol.160, 1387.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A novel, potent, orally bioavailable antagonist of P2X3/P2X2/3 receptors (pIC50 = 8 in human and rat; pIC50 = 7.3 for human P2X2/3 receptor). Shown to be highly brain penetrant with a brain to plasma ratio of 6. Blocks agonist-evoked intracellular Ca2+ flux and inward currents in nanomolar range (10 nM to 1 µM) in cell lines recombinantly expressing human P2X3 and P2X2/3 receptors. Exhibits desirable pharmacokinetic properties (t1/2 = 1.63 h and Tmax = 30 min).
Form
Light brown powder
CAS number
927887-18-1
Chemical formula
C₁₄H₁₈ClIN₄O₂
Purity
≥99% by HPLC
Solubility
DMSO (10 mg/ml)
Storage
+2°C to +8°C
Protect from light
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Standard Handling
References
Gever, J. R., et al. 2010. Br. J. Pharmacol.160, 1387.
